DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20221992
Published: 2022-07-27

Recurrent bilateral superficial vein thrombosis in hereditary hemochromatosis- a case report

Wael Abousherif, Motahareh Vameghestahbanati, Ahmed Hallak

Abstract


We report a rare case of recurrent bilateral superficial vein thrombosis (SVT) in a 45-year-old former smoking male with hereditary hemochromatosis on anticoagulation therapy with unremarkable hypercoagulable workup. This case report adds to the growing evidence that hemochromatosis is one of the rare causes of recurrent SVT, and thrombosis can still occur despite full-dose anticoagulation. Future studies assessing optimal management of the recurrent SVT in hemochromatosis patients are warranted.


Keywords


Hemochromatosis, Superficial vein thrombosis, Thrombosis

Full Text:

PDF

References


Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis. 2002;13(2):80-8.

Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol. 2002;64:663-80.

Janssen MC, Swinkels DW. Hereditary haemochromatosis. Best Pract Res Clin Gastroenterol. 2009;23(2):171-83.

Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation. 1999;100(12):1274-9.

Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100(12):1268-73.

Rasmussen ML, Folsom AR, Catellier DJ, Tsai MY, Garg U, Eckfeldt JH. A prospective study of coronary heart disease and the hemochromatosis gene (HFE) C282Y mutation: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2001;154(3):739-46.

Delval L, Brohee D, Cauchie P, Vanhaeverbeek M, Hilbert P. Acute portal thrombosis revealing hereditary hemochromatosis: report of a case. Rev Med Brux. 2002;23(2):83-6.

Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Ann Hematol. 2008;87(3):167-73.

Rawla. JLPP. Hemochromatosis. StatPearls. Treasure Island (FL): StatPearls Publishing: National Library of Medicine. 2021.

Whittington CA, Kowdley KV. Review article: haemochromatosis. Aliment Pharmacol Ther. 2002;16(12):1963-75.

Barton JC, Edwards CQ, Acton RT. HFE gene: Structure, function, mutations, and associated iron abnormalities. Gene. 2015;574(2):179-92.

Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13(4):399-408.

Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S, et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107(20):2601-6.

MacLean RM, Feeney GP, Bowley SJ, Bowen DJ, Worwood M, Collins PW. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease? Br J Haematol. 1999;107(1):210-2.

Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's Choice - efficacy and safety of the new oral anticoagulants’ dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur J Vasc Endovasc Surg. 2014;48(5):565-75.